Multidrug-resistant Neisseria gonorrhoeae isolates from Nanjing, China, are sensitive to killing by a novel DNA gyrase inhibitor, ETX0914 (AZD0914)

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 1, 2016, Pages 621-623

  Su, Xiao Hong ^a   Wang, Bao Xi ^a   Le, Wen Jing ^a   Liu, Yu Rong ^a   Wan, Chuan ^a   Li, Sai ^a   Alm, Richard A ^b   Mueller, John P ^c   Rice, Peter A ^d  

^a INSTITUTE OF DERMATOLOGY   (China)

^b Macrolide Pharmaceuticals   (United States)

^c Entasis Therapeutics   (United States)

^d UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CIPROFLOXACIN; ZOLIFLODACIN; ANTIINFECTIVE AGENT; BARBITURIC ACID DERIVATIVE; CEFTRIAXONE; DNA TOPOISOMERASE (ATP HYDROLYSING); GYRASE INHIBITOR; SPIRO COMPOUND; TETRACYCLINE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CHINA; GONOCOCCAL URETHRITIS; GONORRHEA; GRAM STAINING; HAEMOPHILUS; HUMAN; IN VITRO STUDY; MALE; MIC50; MIC90; MORAXELLA CATARRHALIS; MULTIDRUG RESISTANCE; NEISSERIA GONORRHOEAE; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION; GENETICS; ISOLATION AND PURIFICATION; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; URETHRITIS;

ANTI-BACTERIAL AGENTS; AZITHROMYCIN; BARBITURATES; CEFTRIAXONE; CIPROFLOXACIN; DNA GYRASE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GENE EXPRESSION; GONORRHEA; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; NEISSERIA GONORRHOEAE; SPIRO COMPOUNDS; TETRACYCLINE; TOPOISOMERASE II INHIBITORS; URETHRITIS;

EID: 84957877111     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01211-15     Document Type: Article

References (28)

1. Unemo M, Golparian D, Syversen G, Vestrheim DF, Moi H. 2010. Two cases of verified clinical failures using internationally recommended first-line cefixime for gonorrhoea treatment, Norway, 2010. Euro Surveill 15: pii=19721. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19721.
2. Ison CA, Hussey J, Sankar KN, Evans J, Alexander S. 2011. Gonorrhoea treatment failures to cefixime and azithromycin in England, 2010. Euro Surveill 16:pii=19833. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19933.
3. Unemo M, Golparian D, Stary A, Eigentler A. 2011. First Neisseria gonorrhoeae strain with resistance to cefixime causing gonorrhoea treatment failure in Austria, 2011. Euro Surveill 216:pii=19998. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19998.
4. Unemo M, Golparian D, Nicholas R, Ohnishi M, Gallay A, Sednaoui P. 2012. High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother 56:1273-1280. http://dx.doi.org/10.1128/AAC.05760-11.
5. Allen VG, Mitterni L, Seah C, Rebbapragada A, Martin IE, Lee C, Siebert H, Towns L, Melano RG, Low DE. 2013. Neisseria gonorrhoeae treatment failure and susceptibility to cefixime in Toronto, Canada. JAMA 309:163-170. http://dx.doi.org/10.1001/jama.2012.176575.
6. Tapsall J, Read P, Carmody C, Bourne C, Ray S, Limnios A, Sloots T, Whiley D. 2009. Two cases of failed ceftriaxone treatment in pharyngeal gonorrhoea verified by molecular microbiological methods. J Med Microbiol 58:683-687. http://dx.doi.org/10.1099/jmm.0.007641-0.
7. Ohnishi M, Saika T, Hoshina S, Iwasaku K, Nakayama S, Watanabe H, Kitawaki J. 2011. Ceftriaxone-resistant Neisseria gonorrhoeae, Japan. Emerg Infect Dis 17:148-149. http://dx.doi.org/10.3201/eid1701.100397.
8. Unemo M, Golparian D, Hestner A. 2011. Ceftriaxone treatment failure of pharyngeal gonorrhoea verified by international recommendations, Sweden, July 2010. Euro Surveill 16:pii=19792. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19792.
9. Unemo M, Golparian D, Potočnik M, Jeverica S. 2012. Treatment failure of pharyngeal gonorrhoea with internationally recommended first-line ceftriaxone verified in Slovenia, September 2011. Euro Surveill 17:20200. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20200.
10. Golparian D, Ohlsson A, Janson H, Lidbrink P, Richtner T, Ekelund O, Fredlund H, Unemo M. 2014. Four treatment failures of pharyngeal gonorrhoea with ceftriaxone (500 mg) or cefotaxime (500 mg), Sweden, 2013 and 2014. Euro Surveill 19:20862. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20862.
11. Kern G, Palmer T, Ehmann DE, Shapiro AB, Andrews B, Basarab GS, Doig P, Fan J, Gao N, Mills SD, Mueller J, Sriram S, Thresher J, Walkup GK. 2015. Inhibition of Neisseria gonorrhoeae type II topoisomerases by the novel spiropyrimidinetrione AZD0914. J Biol Chem 290:20984-20994. http://dx.doi.org/10.1074/jbc.M115.663534.
12. Huband MD, Bradford PA, Otterson LG, Basarab GS, Kutschke AC, Giacobbe RA, Patey SA, Alm RA, Johnstone MR, Potter ME, Miller PF, Mueller JP. 2015. In vitro antibacterial activity of AZD0914, a new spiropyrimidinetrione DNA gyrase/topoisomerase inhibitor with potent activity against Gram-positive, fastidious Gram-negative, and atypical bacteria. Antimicrob Agents Chemother 59:467-474. http://dx.doi.org/10.1128/AAC.04124-14.
13. Jacobsson S, Golparian D, Alm RA, Huband M, Mueller J, Jensen JS, Ohnishi M, Unemo M. 2014. High in vitro activity of the novel spiropyrimidinetrione AZD0914, a DNA gyrase inhibitor, against multidrug-resistant Neisseria gonorrhoeae isolates suggests a new effective option for oral treatment of gonorrhea. Antimicrob Agents Chemother 58:5585-5588. http://dx.doi.org/10.1128/AAC.03090-14.
14. Unemo M, Ringlander J, Wiggins C, Fredlund H, Jacobsson S, Cole M. 2015. High in vitro susceptibility to the novel spiropyrimidinetrione ETX0914 (AZD0914) among 873 contemporary clinical Neisseria gonorrhoeae isolates from 21 European countries from 2012 to 2014. Antimicrob Agents Chemother 59:5220-5225. http://dx.doi.org/10.1128/AAC.00786-15.
15. Biedenbach DJ, Huband MD, Hackel M, de Jonge BL, Sahm DF, Bradford PA. 2015. In vitro activity of AZD0914, a novel bacterial DNA gyrase/topoisomerase IV inhibitor, against clinically relevant Gram-positive and fastidious Gram-negative pathogens. Antimicrob Agents Chemother 59:6053-6063. http://dx.doi.org/10.1128/AAC.01016-15.
16. Alm RA, Lahiri SD, Kutschke A, Otterson LG, McLaughlin RE, Whiteaker JD, Lewis LA, Su X, Huband MD, Gardner H, Mueller JP. 2015. Characterization of the novel DNA gyrase inhibitor AZD0914: low resistance potential and lack of cross-resistance in Neisseria gonorrhoeae. Antimicrob Agents Chemother 59:1478-1486. http://dx.doi.org/10.1128/AAC.04456-14.
17. Su X, Jiang F, Qimuge, Dai X, Sun H, Ye S. 2007. Surveillance of antimicrobial susceptibilities in Neisseria gonorrhoeae in Nanjing, China, 1999-2006. Sex Transm Dis 34:995-999.
18. Yang Y WL ZC, Gu W. 2009. Study of antimicrobial susceptibilities and molecular resistance determines in Neisseria gonorrhoeae isolated in Shanghai. Chin J Lab Med 32:1173-1175.
19. Gu W, Chen Y, Yang Y, Wu L, Hu W, Jin Y. 2014. Twenty-five-year changing pattern of gonococcal antimicrobial susceptibility in Shanghai: surveillance and its impact on treatment guidelines. BMC Infect Dis 14:731. http://dx.doi.org/10.1186/s12879-014-0731-9.
20. Zheng H, Yang B, Wu X, Huang J, Zeng W, Xue Y, Qin X, Lan Y, Tang S, Ou J, Li Y. 2014. Antibiotic susceptibility of Neisseria gonorrhoeae isolates from Guangzhou, China, during 2002-2011. Jpn J Infect Dis 67:288-291. http://dx.doi.org/10.7883/yoken.67.288.
21. Cao WL, Liang JY, Li XD, Bi C, Yang RD, Liang YH, Li P, Zhong DQ, Ye XD, Zhang XB. 2015. Trends in antimicrobial resistance in Neisseria gonorrhoeae isolated from Guangzhou, China, 2000 to 2005 and 2008 to 2013. Sex Transm Dis 42:27-29. http://dx.doi.org/10.1097/OLQ.0000000000000218.
22. Li S, Su XH, Le WJ, Jiang FX, Wang BX, Rice PA. 2014. Antimicrobial susceptibility of Neisseria gonorrhoeae isolates from symptomatic men attending the Nanjing sexually transmitted diseases clinic (2011-2012): genetic characteristics of isolates with reduced sensitivity to ceftriaxone. BMC Infect Dis 14:622. http://dx.doi.org/10.1186/s12879-014-0622-0.
23. Tapsall J. 2001. Antimicrobial resistance in Neisseria gonorrhoeae. WHO/CDS/CSR/DRS/2001.3. World Health Organization, Geneva, Switzerland. http://www.who.int/drugresistance/Antimicrobial-resistance-in-Neisseria-gonorrhoeae.pdf.
24. Workowski KA, Bolan GA. 2015. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recommend Rep 64(RR03):61.
25. Camara J, Serra J, Ayats J, Bastida T, Carnicer-Pont D, Andreu A, Ardanuy C. 2012. Molecular characterization of two high-level ceftriaxone-resistant Neisseria gonorrhoeae isolates detected in Catalonia, Spain. J Antimicrob Chemother 67:1858-1860. http://dx.doi.org/10.1093/jac/dks162.
26. Clinical and Laboratory Standards Institute. 2012. Performance standards for antimicrobial susceptibility testing; 22nd informational supplement. CLSI document M100-S22. Clinical and Laboratory Standards Institute, Wayne, PA.
27. European Committee on Antimicrobial Susceptibility Testing. 2012. Breakpoint tables for interpretation of MICs and zone diameters: version 1.3. European Committee on Antimicrobial Susceptibility Testing, Växjö, Sweden. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST-files/Disk-test-documents/EUCAST-breakpoints-v1.3-pdf.pdf.
28. Sng EH, Yeo KL, Rajan VS. 1981. Simple method for detecting penicillinase-producing Neisseria gonorrhoeae and Staphylococcus aureus. Br J Vener Dis 57:141-142.